Post-Transplant Outcomes in High-Risk Compared With Non-High-Risk Multiple Myeloma: A CIBMTR Analysis

In conclusion, we show HRM patients achieve similar day 100 post-transplant responses compared with non-HRM patients, but these responses are not sustained. Post-transplant therapy appeared to improve the poor outcomes of HRM.

 Biol Blood Marrow Transplant

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.